6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Neuroinflammation and Substance Use Disorders
Neuroinflammation refers to inflammation in the brain, which can be triggered by chronic substance use. This inflammation plays a significant role in the development and progression of substance use disorders by altering neural signaling, neurotransmitter systems, and brain structure. Persistent neuroinflammation can lead to cognitive deficits, emotional dysregulation, and a heightened susceptibility to addiction. Recent research suggests that targeting neuroinflammation may be a promising avenue for addiction treatment, as reducing inflammation could potentially reverse some of the cognitive and emotional impairments caused by substance use. Anti-inflammatory treatments, alongside traditional therapies, may provide new hope for individuals struggling with addiction.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States